Eli Lilly ne India mein lagaye ‌‌‌**$1 Billion**! Pharma giants ke liye policy rules zaroori, warna investment mushkil

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Eli Lilly ne India mein lagaye ‌‌‌**$1 Billion**! Pharma giants ke liye policy rules zaroori, warna investment mushkil
Overview

Bhaiyon, ek badi khabar hai pharma world se! Eli Lilly, jo ki ek top global company hai, India mein **$1 billion** ka investment karne jaa rahi hai. Isse India mein manufacturing capacity badhegi aur AI use karke naye drugs discover karne mein help milegi.

Pharma ka Super Deal: India mein $1 Billion Laga rahi hai Eli Lilly!

Arre suno suno! Eli Lilly ne India mein apna game big time badha diya hai. Company $1 billion US Dollars ka paisa India mein daal rahi hai, taki woh yahan apni manufacturing sites ko badha sake. Yeh paisa Hyderabad aur Bengaluru mein jayega. Aur maze ki baat yeh hai ki woh Nvidia jaise partners ke saath milkar AI (Artificial Intelligence) ka use karke naye-new drugs discover karne ki speed ko bhi tez karenge. Socho, ek taraf capacity badhana, doosri taraf cutting-edge tech use karna! Abhi Eli Lilly ka market valuation lagbhag $810 billion ke aas paas hai, aur unka P/E ratio bhi 75 hai, matlab market unse bahut zyada expect kar raha hai.

Policy Rules Nahi Toh Investment Kaise? (Patrik Jonsson ka Point)

Lekin asli masala yahi hai! Eli Lilly ke ek senior executive, Patrik Jonsson, ne bahut saaf-saaf kaha hai ki agar India ko pharma innovation ka global hub banana hai, toh government ko kuch cheezein theek karni hongi. Unko chahiye predictable aur innovation-friendly regulatory frameworks. Matlab aise rules jo naye ideas ko support karein, na ki un par rok lagayein. Sabse zaroori hai strong intellectual property (IP) protection. Sirf generic drugs banane se kaam nahi chalega, high-risk research and development (R&D) ke liye companies ko bharosa hona chahiye ki unke innovations safe hain. Tabhi bade global investments India mein aa sakte hain. Pfizer aur Novartis jaise competitors bhi yahi same baat baar baar keh rahe hain.

India Market Ke Challenges Aur Future

Dekho, India ka pharma market itna bhi aasan nahi hai. Yahan pehle se hi pricing pressures, zabardast generic competition aur kaafi complex regulatory processes hain. Eli Lilly jaise bade players ko yeh sab manage karna padega. Compulsory licensing ko lekar jo debate chalta rehta hai, woh bhi ek risk factor hai jo innovators ko dara sakta hai. Toh yeh $1 billion ka investment manufacturing ke liye bahut achha hai, par sach mein agar India R&D mein bhi world leader banna chahta hai, toh government ko ek clear aur supportive policy environment banana hi hoga. Warna saara focus sirf manufacturing par hi reh jayega, R&D wala magic nahi ho payega.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.